Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2026 17:05 ET | Source: North American Construction Group Ltd.

North American Construction Group Ltd. Announces Voting Results of Annual and Special Meeting of Shareholders

ACHESON, Alberta, May 21, 2026 (GLOBE NEWSWIRE) -- North American Construction Group Ltd. (“NACG” or “the Company”) (TSX:NOA/NYSE:NOA) today announced the results of its Annual and Special Meeting...
May 21, 2026 17:05 ET | Source: Eikon Therapeutics, Inc.

Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology

The six accepted presentations highlight clinical progress across Eikon’s pipeline.
May 21, 2026 17:05 ET | Source: Remix Therapeutics

Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical Oncology Annual Meeting 2026

Phase 1 Data Shows a 43% Overall Response Rate at the Recommended Phase 2 Dose and Durable Responses Exceeding One Year and Ongoing, with a Favorable Safety Profile Anti-Tumor Activity Seen Across...
May 21, 2026 17:02 ET | Source: Imperial Metals Corporation

Imperial Announces Voting Results for the Election of Directors

VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- Imperial Metals Corporation (“Imperial” or the “Company”) (TSX:III) reports, in accordance with the policies of the Toronto Stock...
May 21, 2026 17:02 ET | Source: Moleculin Biotech, Inc.

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin

HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract featuring pooled cardiac safety data for its lead...
May 21, 2026 17:01 ET | Source: Regeneron Pharmaceuticals, Inc.

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

Normalization of free light chains occurred by day 15 across all doses 100% of patients achieved a hematologic complete response (CR) at the highest tested dose Majority of patients with renal or...
May 21, 2026 17:01 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models

An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic activity against KRAS G12D and G12C- driven pancreatic cancer modelsData...
May 21, 2026 17:01 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant – – Data underscoring...
May 21, 2026 17:01 ET | Source: The Rosen Law Firm PA

ALDX DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3,...
May 21, 2026 17:00 ET | Source: AerSale Inc

AerSale Announces Participation at the 2026 Jefferies Aftermarket MRO Virtual Summit

MIAMI, May 21, 2026 (GLOBE NEWSWIRE) -- AerSale Corporation (NASDAQ: ASLE) (the “Company”), today announced that the Company’s Chief Financial Officer, Martin Garmendia will present at the 2026...

1 ...1875 1876 1877 ...326070